254 related articles for article (PubMed ID: 37253111)
1. Immunogenetic Metabolomics Reveals Key Enzymes That Modulate CAR T-cell Metabolism and Function.
Renauer P; Park JJ; Bai M; Acosta A; Lee WH; Lin GH; Zhang Y; Dai X; Wang G; Errami Y; Wu T; Clark P; Ye L; Yang Q; Chen S
Cancer Immunol Res; 2023 Aug; 11(8):1068-1084. PubMed ID: 37253111
[TBL] [Abstract][Full Text] [Related]
2. Immunogenetic metabolomics revealed key enzymes that modulate CAR-T metabolism and function.
Renauer P; Park JJ; Bai M; Acosta A; Lee WH; Lin GH; Zhang Y; Dai X; Wang G; Errami Y; Wu T; Clark P; Ye L; Yang Q; Chen S
bioRxiv; 2023 Mar; ():. PubMed ID: 36993638
[TBL] [Abstract][Full Text] [Related]
3. Adenosine Deaminase 1 Overexpression Enhances the Antitumor Efficacy of Chimeric Antigen Receptor-Engineered T Cells.
Qu Y; Dunn ZS; Chen X; MacMullan M; Cinay G; Wang HY; Liu J; Hu F; Wang P
Hum Gene Ther; 2022 Mar; 33(5-6):223-236. PubMed ID: 34225478
[TBL] [Abstract][Full Text] [Related]
4. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells.
Bai Z; Lundh S; Kim D; Woodhouse S; Barrett DM; Myers RM; Grupp SA; Maus MV; June CH; Camara PG; Melenhorst JJ; Fan R
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006631
[TBL] [Abstract][Full Text] [Related]
5. Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo.
Liu G; Zhang Q; Liu G; Li D; Zhang L; Gu Z; Tian H; Zhang Y; Tian X
Exp Cell Res; 2021 Dec; 409(1):112886. PubMed ID: 34673000
[TBL] [Abstract][Full Text] [Related]
6. Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors.
Johnson A; Townsend M; O'Neill K
Cells; 2022 Nov; 11(22):. PubMed ID: 36429054
[TBL] [Abstract][Full Text] [Related]
7. Cell metabolism-based optimization strategy of CAR-T cell function in cancer therapy.
Li W; Pan X; Chen L; Cui H; Mo S; Pan Y; Shen Y; Shi M; Wu J; Luo F; Liu J; Li N
Front Immunol; 2023; 14():1186383. PubMed ID: 37342333
[TBL] [Abstract][Full Text] [Related]
8. CAR T-cells for colorectal cancer immunotherapy: Ready to go?
Ghazi B; El Ghanmi A; Kandoussi S; Ghouzlani A; Badou A
Front Immunol; 2022; 13():978195. PubMed ID: 36458008
[TBL] [Abstract][Full Text] [Related]
9. Targeting of chimeric antigen receptor T cell metabolism to improve therapeutic outcomes.
Nanjireddy PM; Olejniczak SH; Buxbaum NP
Front Immunol; 2023; 14():1121565. PubMed ID: 36999013
[TBL] [Abstract][Full Text] [Related]
10. Coengineering specificity, safety, and function into T cells for cancer immunotherapy.
Giordano Attianese GMP; Ash S; Irving M
Immunol Rev; 2023 Nov; 320(1):166-198. PubMed ID: 37548063
[TBL] [Abstract][Full Text] [Related]
11. Enhanced tumor immunotherapy by polyfunctional CD19-CAR T cells engineered to secrete anti-CD47 single-chain variable fragment.
Qiu Y; Liao P; Wang H; Chen J; Hu Y; Hu R; Zhang H; Li Z; Cao M; Yang Y; Li M; Xie X; Li Y
Int J Biol Sci; 2023; 19(15):4948-4966. PubMed ID: 37781520
[TBL] [Abstract][Full Text] [Related]
12. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
Martinez M; Moon EK
Front Immunol; 2019; 10():128. PubMed ID: 30804938
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
14. Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion.
Gumber D; Wang LD
EBioMedicine; 2022 Mar; 77():103941. PubMed ID: 35301179
[TBL] [Abstract][Full Text] [Related]
15. Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies.
Li YR; Halladay T; Yang L
J Biomed Sci; 2024 Jan; 31(1):5. PubMed ID: 38217016
[TBL] [Abstract][Full Text] [Related]
16. CAR-tropic extracellular vesicles carry tumor-associated antigens and modulate CAR T cell functionality.
Ukrainskaya VM; Musatova OE; Volkov DV; Osipova DS; Pershin DS; Moysenovich AM; Evtushenko EG; Kulakovskaya EA; Maksimov EG; Zhang H; Rubtsov YP; Maschan MA; Stepanov AV; Gabibov AG
Sci Rep; 2023 Jan; 13(1):463. PubMed ID: 36627334
[TBL] [Abstract][Full Text] [Related]
17. D2HGDH-mediated D2HG catabolism enhances the anti-tumor activities of CAR-T cells in an immunosuppressive microenvironment.
Yang Q; Hao J; Chi M; Wang Y; Li J; Huang J; Zhang J; Zhang M; Lu J; Zhou S; Yuan T; Shen Z; Zheng S; Guo C
Mol Ther; 2022 Mar; 30(3):1188-1200. PubMed ID: 35007759
[TBL] [Abstract][Full Text] [Related]
18. The altering cellular components and function in tumor microenvironment during remissive and relapsed stages of anti-CD19 CAR T-cell treated lymphoma mice.
Zhao K; Ren C; Tang D; Zhao L; Chen X; Wang Y; Xu K
Front Immunol; 2023; 14():1101769. PubMed ID: 36761733
[TBL] [Abstract][Full Text] [Related]
19. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.
Zolov SN; Rietberg SP; Bonifant CL
Cytotherapy; 2018 Oct; 20(10):1259-1266. PubMed ID: 30309710
[TBL] [Abstract][Full Text] [Related]
20. Tumor microenvironment and CAR-T cell immunotherapy in B-cell lymphoma.
Cai F; Zhang J; Gao H; Shen H
Eur J Haematol; 2024 Feb; 112(2):223-235. PubMed ID: 37706523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
